Blood biomarkers of bone metastasis in digestive tract malignant tumors.
Xiaoting MaYichang FanZhaoxin ChenYujian ZhangShan WangJing YuPublished in: Future oncology (London, England) (2021)
Aim: To evaluate the role of clinical features and blood markers in patients with malignant digestive tract tumors bone metastasis. Materials & methods: A total of 267 patients were included in this trial. Age, gender, primary tumor site, metastatic sites, T/N stage, high-density lipoprotein, low-density lipoprotein, total cholesterol, triglycerides, alkaline phosphatase, LDH, Ca levels, platelet, neutrophils to absolute value of lymphocytes (NLR), ratio of platelets to absolute values of lymphocytes (PLR) were analyzed. Results: T stage, lymph node metastasis, N stage and liver and lung metastasis were independent risk factors. LDH + alkaline phosphatase + NLR + PLR and LDH + NLR, respectively have higher predictive value for bone metastasis compared with patients with early-stage malignant digestive tract tumor and patients with advanced malignant digestive tract tumor without bone metastasis. Conclusion: Some clinical features or blood markers have the potential to detect bone metastasis early to avoid skeletal complications.
Keyphrases
- risk assessment
- human health
- bone mineral density
- low density lipoprotein
- high density
- early stage
- lymph node metastasis
- risk factors
- squamous cell carcinoma
- bone loss
- small cell lung cancer
- bone regeneration
- end stage renal disease
- clinical trial
- postmenopausal women
- peripheral blood
- ejection fraction
- study protocol
- peritoneal dialysis
- newly diagnosed
- lymph node
- body composition
- climate change
- phase ii
- papillary thyroid